National guidelines for diagnosis and treatment of cervical cancer 2022 in China (English version).
出版信息
Chin J Cancer Res. 2022 Jun 30;34(3):256-269. doi: 10.21147/j.issn.1000-9604.2022.03.06.
Abstract
摘要
相似文献
1
National guidelines for diagnosis and treatment of cervical cancer 2022 in China (English version).
Chin J Cancer Res. 2022 Jun 30;34(3):256-269. doi: 10.21147/j.issn.1000-9604.2022.03.06.
2
Comments on .
Chin J Cancer Res. 2022 Oct 30;34(5):458-459. doi: 10.21147/j.issn.1000-9604.2022.05.06.
3
National Health Commission guidelines for diagnosis and treatment of colorectal cancer 2023 in China (English version).
Chin J Cancer Res. 2023 Jun 30;35(3):197-232. doi: 10.21147/j.issn.1000-9604.2023.03.01.
4
Comments on .
Chin J Cancer Res. 2023 Oct 30;35(5):431-432. doi: 10.21147/j.issn.1000-9604.2023.05.01.
5
National guidelines for diagnosis and treatment of breast cancer 2022 in China (English version).
Chin J Cancer Res. 2022 Jun 30;34(3):151-175. doi: 10.21147/j.issn.1000-9604.2022.03.02.
6
National guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version).
Chin J Cancer Res. 2020 Aug;32(4):415-445. doi: 10.21147/j.issn.1000-9604.2020.04.01.
7
National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version).
Chin J Cancer Res. 2022 Jun 30;34(3):131-150. doi: 10.21147/j.issn.1000-9604.2022.03.01.
8
National guidelines for diagnosis and treatment of gastric cancer 2022 in China (English version).
Chin J Cancer Res. 2022 Jun 30;34(3):207-237. doi: 10.21147/j.issn.1000-9604.2022.03.04.
9
National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version).
Chin J Cancer Res. 2022 Jun 30;34(3):270-288. doi: 10.21147/j.issn.1000-9604.2022.03.07.
10
National guidelines for diagnosis and treatment of lung cancer 2022 in China (English version).
Chin J Cancer Res. 2022 Jun 30;34(3):176-206. doi: 10.21147/j.issn.1000-9604.2022.03.03.
引用本文的文献
1
Prevalence and genotype distribution of human papillomavirus (HPV) infections among West African populations: a systematic review and meta-analysis.
Infect Agent Cancer. 2025 Sep 1;20(1):62. doi: 10.1186/s13027-025-00659-x.
2
VETC predicting model based on CE-CT can predict prognosis and assisting treatment plan for solitary HCC: better together with radiomics.
BMC Cancer. 2025 Jul 1;25(1):1033. doi: 10.1186/s12885-025-14408-1.
3
Cost-benefit analysis of p16 immunocytology and liquid-based cytology triage after primary HPV testing for cervical cancer screening in China.
Infect Agent Cancer. 2025 Apr 18;20(1):26. doi: 10.1186/s13027-025-00642-6.
4
Preoperative prediction of recurrence risk factors in operable cervical cancer based on clinical-radiomics features.
Front Oncol. 2025 Feb 28;15:1492494. doi: 10.3389/fonc.2025.1492494. eCollection 2025.
5
Interrelation between dyadic coping and psychological resilience among cervical cancer couples in Northwest China: An Actor-Partner interdependence model.
Asia Pac J Oncol Nurs. 2024 Nov 15;11(12):100615. doi: 10.1016/j.apjon.2024.100615. eCollection 2024 Dec.
6
Prevalence and Genotyping of Human Papillomavirus Infections in Females and Males in Zhejiang, China.
Infect Drug Resist. 2024 Nov 29;17:5325-5334. doi: 10.2147/IDR.S484519. eCollection 2024.
7
Sintilimab plus HPV vaccine for recurrent or metastatic cervical cancer.
J Immunother Cancer. 2024 Nov 27;12(11):e009898. doi: 10.1136/jitc-2024-009898.
8
Efficacy of total laparoscopic hysterectomy without uterine manipulators in patient with early-stage cervical cancer.
Pak J Med Sci. 2024 Nov;40(10):2428-2431. doi: 10.12669/pjms.40.10.10093.
9
Polymorphisms in miRNA Genes Targeting the AMPK Signaling Pathway are Associated with Cervical Cancer Susceptibility in a Han Chinese Population.
Int J Gen Med. 2024 Sep 16;17:4171-4188. doi: 10.2147/IJGM.S473133. eCollection 2024.
10
Impact of competition on reimbursement decisions for cancer drugs in China: an observational study.
Lancet Reg Health West Pac. 2024 Jul 25;50:101157. doi: 10.1016/j.lanwpc.2024.101157. eCollection 2024 Sep.
Zotero 插件